-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Yan’an Bikang Pharmaceutical Co.
, Ltd.
(“Yan’an Bikang”) issued an announcement stating that it has signed an agreement of intent to purchase assets with Nanhua Biotechnology to sell some of the medical assets held by Yan’an Bikang, and also received Jiangsu Provincial letter on the pre-examination of new energy project expansion
.
Regarding the asset sale, the company stated that it is to gradually divest the pharmaceutical business, further improve and adjust the company's industry and investment structure, and focus more on the development of the new energy and new materials industry
.
It is reported that Nanhua Biotechnology intends to acquire the equity of some pharmaceutical companies and pharmaceutical circulation companies under Yan'an Bikang and/or the assets corresponding to some production workshops.
The specific scope of target assets will be determined by the two parties after due diligence
.
Public information shows that Yan'an Bikang’s main business includes four major categories: the pharmaceutical industry sector, the pharmaceutical business sector, the new energy and new materials sector, and the pharmaceutical intermediate sector
.
The main products are Fengtongning Tablets, Compound Danshen Tablets, Pediatric Phlegm Relieving Cough Granules, Yinqiao Jiedu Granules, and Pediatric Cold Granules
.
In 2015, Yanan Bikang's backdoor holding subsidiary Jiujiujiu was listed on the Shenzhen Stock Exchange, and subsequently continued to acquire and expand in the pharmaceutical sector, including the acquisition of subsidiaries Jiangsu Xiaoying Pharmaceutical Co.
, Ltd.
, Bikang Runxiang Pharmaceutical Hebei Co.
, Ltd.
, and Bikang Baichuan Pharmaceutical (Henan) Co.
, Ltd.
and so on
.
Under these layouts, Yan'an Bikang has achieved continuous growth in performance
.
In 2016, Yan'an Bikang's revenue was 3.
724 billion yuan, and by 2019 it has risen to 9.
328 billion yuan
.
However, by 2020, affected by the epidemic and other aspects, Yan'an Bikang’s performance has begun to change its face.
In that year, its annual revenue was only 6.
953 billion yuan, a year-on-year decrease of 25.
46%, and a net profit loss of 1.
071 billion yuan, a year-on-year decrease of 367.
64%
.
In order to withdraw funds, Yan'an Bikang started the sale of its subsidiaries.
Since 2020, it has sold 100% of its subsidiary Wuhan Wujing Pharmaceutical Co.
, Ltd.
, and plans to transfer 74.
24% of Jiujiujiu's shares to Xinzhoubang, although the transaction is terminated.
Come to an end
.
Now the company has announced the sale of some pharmaceutical assets, which shows that its transformation and upgrading is accelerating
.
Regarding the company's new energy layout, the analysis believes that since 2020, the price of new energy product lithium hexafluorophosphate has been rising, from less than 70,000 yuan/ton in July 2020 to over 450,000/ton in August 2021.
Ton, Yan’an Bikang has not been successfully transferred before, Jiujiujiu is an enterprise engaged in the research and development and production of lithium hexafluorophosphate.
Currently, Yan’an Bikang’s existing lithium hexafluorophosphate plant has a design capacity of 5,000 tons per year.
After energy-saving potential and optimization transformation, the actual production capacity is Reach 6,400 tons/year
.
Or take the new energy "express", Yan'an Bikang's performance began to improve in the first three quarters of this year.
In the first nine months of 2021, it achieved 5.
591 billion yuan, an increase of 8.
8% year-on-year, and its net profit was 609 million yuan, an increase of 4672.
62% year-on-year
.
At the same time, Yan'an Bikang's stock price has also grown rapidly
.
Data shows that at the beginning of 2021, Yan'an Bikang’s stock price was 4.
15 yuan per share.
By September of this year, the stock price had soared to 17.
99 yuan per share, an increase of over 300%
.
In recent years, the medical reform environment has changed, and the performance of pharmaceutical companies has been under obvious pressure.
In order to withdraw funds to focus on the main business, it is no longer uncommon for pharmaceutical companies to divest pharmaceutical assets
.
According to incomplete statistics, since December, in addition to Yan'an Bikang, other pharmaceutical companies such as Kang En Bay, Xiangxue Pharmaceutical, Jingfeng Pharmaceutical, Xilong Science, and Meikang Biological have all issued relevant announcements on asset sales, and the pharmaceutical industry has transformed.
The road is continuing
.
, Ltd.
(“Yan’an Bikang”) issued an announcement stating that it has signed an agreement of intent to purchase assets with Nanhua Biotechnology to sell some of the medical assets held by Yan’an Bikang, and also received Jiangsu Provincial letter on the pre-examination of new energy project expansion
.
Regarding the asset sale, the company stated that it is to gradually divest the pharmaceutical business, further improve and adjust the company's industry and investment structure, and focus more on the development of the new energy and new materials industry
.
It is reported that Nanhua Biotechnology intends to acquire the equity of some pharmaceutical companies and pharmaceutical circulation companies under Yan'an Bikang and/or the assets corresponding to some production workshops.
The specific scope of target assets will be determined by the two parties after due diligence
.
Public information shows that Yan'an Bikang’s main business includes four major categories: the pharmaceutical industry sector, the pharmaceutical business sector, the new energy and new materials sector, and the pharmaceutical intermediate sector
.
The main products are Fengtongning Tablets, Compound Danshen Tablets, Pediatric Phlegm Relieving Cough Granules, Yinqiao Jiedu Granules, and Pediatric Cold Granules
.
In 2015, Yanan Bikang's backdoor holding subsidiary Jiujiujiu was listed on the Shenzhen Stock Exchange, and subsequently continued to acquire and expand in the pharmaceutical sector, including the acquisition of subsidiaries Jiangsu Xiaoying Pharmaceutical Co.
, Ltd.
, Bikang Runxiang Pharmaceutical Hebei Co.
, Ltd.
, and Bikang Baichuan Pharmaceutical (Henan) Co.
, Ltd.
and so on
.
Under these layouts, Yan'an Bikang has achieved continuous growth in performance
.
In 2016, Yan'an Bikang's revenue was 3.
724 billion yuan, and by 2019 it has risen to 9.
328 billion yuan
.
However, by 2020, affected by the epidemic and other aspects, Yan'an Bikang’s performance has begun to change its face.
In that year, its annual revenue was only 6.
953 billion yuan, a year-on-year decrease of 25.
46%, and a net profit loss of 1.
071 billion yuan, a year-on-year decrease of 367.
64%
.
In order to withdraw funds, Yan'an Bikang started the sale of its subsidiaries.
Since 2020, it has sold 100% of its subsidiary Wuhan Wujing Pharmaceutical Co.
, Ltd.
, and plans to transfer 74.
24% of Jiujiujiu's shares to Xinzhoubang, although the transaction is terminated.
Come to an end
.
Now the company has announced the sale of some pharmaceutical assets, which shows that its transformation and upgrading is accelerating
.
Regarding the company's new energy layout, the analysis believes that since 2020, the price of new energy product lithium hexafluorophosphate has been rising, from less than 70,000 yuan/ton in July 2020 to over 450,000/ton in August 2021.
Ton, Yan’an Bikang has not been successfully transferred before, Jiujiujiu is an enterprise engaged in the research and development and production of lithium hexafluorophosphate.
Currently, Yan’an Bikang’s existing lithium hexafluorophosphate plant has a design capacity of 5,000 tons per year.
After energy-saving potential and optimization transformation, the actual production capacity is Reach 6,400 tons/year
.
Or take the new energy "express", Yan'an Bikang's performance began to improve in the first three quarters of this year.
In the first nine months of 2021, it achieved 5.
591 billion yuan, an increase of 8.
8% year-on-year, and its net profit was 609 million yuan, an increase of 4672.
62% year-on-year
.
At the same time, Yan'an Bikang's stock price has also grown rapidly
.
Data shows that at the beginning of 2021, Yan'an Bikang’s stock price was 4.
15 yuan per share.
By September of this year, the stock price had soared to 17.
99 yuan per share, an increase of over 300%
.
In recent years, the medical reform environment has changed, and the performance of pharmaceutical companies has been under obvious pressure.
In order to withdraw funds to focus on the main business, it is no longer uncommon for pharmaceutical companies to divest pharmaceutical assets
.
According to incomplete statistics, since December, in addition to Yan'an Bikang, other pharmaceutical companies such as Kang En Bay, Xiangxue Pharmaceutical, Jingfeng Pharmaceutical, Xilong Science, and Meikang Biological have all issued relevant announcements on asset sales, and the pharmaceutical industry has transformed.
The road is continuing
.
